Anti-infection immunity and vaccine research (DongmingZhou)
Vaccination is generally considered to be the most effective method of preventing infectious diseases or some other diseases. Adenovirus (Ad) is the most promising vector in vaccine research, which can induce not only potent humoral immune responses but also cellular immune responses. So it has been widely used in many studies including vaccine development for infectious diseases and cancer. Till now most vectors have been based on human serotype 5(AdHu5). This virus is endemic in most human populations and neutralizing antibodies specific to AdHu5 can be detected in up to 40-60% of humans. Pre-existing neutralizing antibodies dampen the efficacy of gene transfer and increase vector-mediated toxicity. Vectors based on rare serotypes of human Ad or Ad derived from other species are being explored to overcome the impact of pre-existing immunity.
Chimpanzee adenovirus typically neither circulates in humans nor cross-reacts with human serotypes, so there is no pre-existing neutralizing antibody to chimpanzee adenovirus in humans. Vaccine based on chimpanzee adenoviral vector will induce much better immune efficacy than that based on AdHu5. The goal of our laboratory is to generate various chimpanzee adenoviruses as vaccine vectors, set up platforms for vaccine development based on recombinant adenoviruses. Based on recombinant adenoviral vectors, we develop novel universal vaccine to influenza, new HIV vaccine, vaccines against hand foot and mouth disease and other certain infectious diseases or cancer, and explore the mechanisms involved in the immune protection induced by these vaccines. These studies will provide new strategies and approaches for prevention or treatment of some certain diseases.